DEMOGRAPHICS

1)	Patient Study Code:				
2)	Patient Hospital Medical Record Number:				
3)	Patient Name:				
4)	Date of birth /				
5)	Gender: ☐ Male ☐ Female				
6)	Ethnicity: Kinh Other (specify)				
7)	Nationality: Vietnam Other (specify)				
8)	Patient Address: Number/Street Commune District City				
9)	Referred from Home/Family District Hospital City Hospital Date of admission to local hospital (if applicable)				
10)	Date of admission to National Hospital / / / / / / / / / / / / / / / / / / /				
11)	Date of discharge from National Hospital / / / / / / / / / / / / / / / / / / /				
12)	Discharged to □Deceased □Home/Family □District Hospital □City Hospital → see q.12a → see q.12a				
	a) If transferred to other hospital, list hospital address: Number/Street Commune District				
CLINIC	CAL CHARACTERISTIC				

Patient code

13) Sites of TB (mark all applicable)							
□ Pulm	•	→ answer 15a					
□ Pleu		→ answer 15b					
	phatic - Extrathorad						
☐ Men	•	→ answer 15d					
⊔ Oste	oarticular	→ answer 15e					
	Specify: ☐ Skele						
	☐ Long	oone					
	□ Joint						
	☐ Other						
☐ Abdo		→ answer 15f					
	Specify: Perito						
	☐ Intest ☐ Other						
□ NAII:							
	ary/ Disseminated er (specify)						
Unkı							
14)	Systemic Sympto	ns	Dura	ition (Leave blank if unknown)			
	□ Fever			days			
	☐ Fatigue			days			
	□ Weight-loss or	failure to gain weight approp	iately	days			
15)	Focal Symptoms:		Dura	ation (Leave blank if unknown)			
a)	Pulmonary TB	☐ Cough		days			
		☐ Hemoptysis		days			
		□ Dyspnea		days			
		☐ Other		days			
b)	Pleural TB	☐ Cough		days			
		☐ Chest pain		days			
		☐ Dyspnea		days			
		□ Other		days			
c)	TB Meningitis	☐ Headache		days			
		□ Nausea		days			
		☐ Seizure		days			
		☐ Drowsiness, disorientation		days			
		☐ Cranial nerve palsies		days			
		☐ Coma ☐ Hemiplegia/Quadriplegia		days			
		☐ Other		days days			
۹)	TR Lymphadenitis	☐ Lymphadenopathy		days days			
	Osteoarticular TB			days days			
۷,	Osteoarticular 15	☐ Kyphosis		days days			
		☐ Altered gait		days days			
		☐ Other		days days			
f)	Abdominal TB	☐ Abdominal Pain		days			
,	-	☐ Nausea/Vomiting		days			
		☐ Diarrhea		, days			
		☐ Other		days			

Patient code

16)	Prem □Y	naturit	y:		lN						
17)	Birth	Weig		kg							
18)	\square Y				dical problems IN						
19)	Histo □Y	ory of ⁻	ГВ сс	ntac							
20)	Adm	ission	Heig cm								
21)	Adm	ission 	Weig	ght: Kg							
22)	□Y a)	if yes, Pulr Pleu Lym Ostr Sp Abo Sp Milli Oth	whamona ural aphataninge eoarth opecify loming er (s ary/er (s anow was a) a) b) b	t wee ary tic - I eal ticula ticula from Diss pecific patic es, lin 2SH 2SH 2SH CCC 6HE 4HF	re sites of disest resites of disest resites of disest resident re	ase?	prior to a	□N	□Unknown		
Patient	code									Page 3 o	f 7

	2. 1	If yes, w Com Cure treatm In pr If i Defa	pleted (treath d (treatment ent and one p ogress n progress, ho ulted (treatm	nent completion) completion and sporevious occasion) ow many days of tent interrupted fo	us prior to admission to Nation outum microscopy negative for the same of the	r AFB at the end of
23)	Tuberculin S		(Mantoux) re	sult:		
24)	BCG Vaccina □Y		No/Unknown			
25)	HIV Status □Positive		Negative	□Unknown		
Diagn	ostics					
26)	□ Lo □ C □ M □ Ir □ M □ P	mal, whobar cor avitary l dicronoc atrathor diliary leural et	Abnormal nat is pattern on nsolidation lesion dular lesions acic adenopat		mark all applicable)	
27)	a) Location B Cly	n: one ymph no kin iver one man other (sp	rrow pecify) uberculosis (ca	aseating epithelio	id granuloma) sis (noncaseating granuloma)	
28)	Culture and I			Source:	AFB Smear:	M.tb Culture:
Patient (code					Page 4 of 7

				_+ _+ _+ _+ _+	 	-+ -+ -+ -+	- - - - -		
		04 Pleural fluid 05 CSF 06 LN biopsy	08	Urine Other biops Other fluid	sy (specify) (specify)				
	a) If culture is positiv Rifampin INH PZA EMB Strep	e, indicate resistan Sensitive	nce pattern: Resistant □ □ □ □ □ □ □ □						
Treat	ment Regimen								
29)		ify)ify)							
20)	b) Documented durat			ays					
30)	Was treatment interrupted during this hospitalization? ☐Y ☐N a) If yes, what was reason for interruption?								
Were there adverse events to therapy requiring discontinuation? □Y □N → skip to q.33 a) If yes, after how many days?days b) If yes, what was adverse reaction? □hepatotoxicity □rash □nausea/vomiting □arthritis □optic neuritis									

Patient code Page 5 of 7

		□other (specify)						
	c)	If yes, to what drug?						
		□INH						
		☐Rifampin						
		□PZA						
		Other (specify)						
		If yes, what is alternate regimen used?						
	e)	If yes, documented duration of alternative regimen at National Hospital days						
32)		ere there adverse events to alternative regimen requiring discontinuation?						
	□Y							
	f)	If yes, after how many days?days						
	g)	If yes, what was adverse reaction?						
		□hepatotoxicity □rash						
		☐nausea/vomiting						
		□arthritis						
		□optic neuritis						
		□other (specify)						
	h)	If yes, to what drug?						
	,							
		□Rifampin						
		□PZA						
		□Other (specify)						
	i)	If yes, what is alternate regimen used?						
	j)	If yes, documented duration at National Hospital days						
33)		ere steroids used?						
	-, □,	The state of the s						
	a)	If yes, which drug						
		□Methylprednisolone □Other						
	h)							
		If yes, list dosemg If yes, planned duration days						
	d)	·						
34)	W∈ □Y	re any THERAPEUTIC surgical intervention performed? ☐N						
		es, please specify procedure:						
	Dat	te:						

Patient code Page 6 of 7

OUTCOME

If dece	ased, disregard th	nis section.							
35)	Discharge Weight: kg								
36)	Discharge Height: cm								
37)	Documented st	tatus at time of di	scharge						
·	□Resolved	□Improved	□No change	□Worse	□Unavailable → see q.37a				
	a) If documented status is unavailable, what is status of systemic signs and focal symptoms (q.14 a								
	q.15) at tir	ne of discharge ba	ased on progress n	otes at time of	f discharge:				
	□Improved □No change □Worse □Unable to assess								